RJFSA
JNCE

Raymond James Financial Services Advisors’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Raymond James Financial Services Advisors’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,427
Closed -$101K – 3118
2020
Q3 		$101K Sell
12,427
-5,202
-30% -$32.3K ﹤0.01% 2694
2020
Q2 		$122K Buy
+17,629
New +$95.1K ﹤0.01% 2602

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Raymond James Financial Services Advisors's JNCE Position: Q4 2020 in Review

Raymond James Financial Services Advisors sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2020, closing a stake of 12,427 shares — an estimated $101K sold.

Raymond James Financial Services Advisors first reported a position in JNCE in Q2 2020 and held it in 2 quarters. The position peaked at $122K in Q2 2020. 104 funds tracked by Wall St. Rank hold JNCE as of Q4 2020.

  • Raymond James Financial Services Advisors reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 12,427 Jounce Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $101K.
  • Raymond James Financial Services Advisors first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Jounce Therapeutics, Inc. Common Stock position peaked at $122K in Q2 2020.
  • 104 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.